Merck considering purchase of cancer drug maker Seagen, WSJ reports – Reuters

Signage is seen at the Merck & Co. headquarters in Kenilworth, New Jersey, U.S., November 13, 2021. REUTERS/Andrew Kelly/File Photo
June 17 (Reuters) – Drugmaker Merck & Co (MRK.N) is considering buying cancer-focused biotech company Seagen Inc (SGEN.O), the Wall Street Journal reported on Friday, citing people familiar with the matter.
Talks have been underway for a while and a deal is not imminent because of heightened risk of a regulatory challenge, the Journal reported, adding that it was also possible the two companies could end up signing a marketing agreement instead.
Seagen, which has a market capitalization of $27 billion according to Refinitiv data, is also being looked at by other unnamed suitors, the paper said.
When contacted by Reuters, Seagen said it does not comment on market rumors or speculation. Merck was not immediately available for comment.
Seagen shares rose 15% to $169.17 in late morning trading on Friday.
Our Standards: The Thomson Reuters Trust Principles.
U.S. biotech firm Moderna will build a new research and manufacturing centre in Britain to develop vaccines against new COVID-19 variants and other illnesses, the government said on Wednesday.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved


Leave a Reply

Your email address will not be published.